Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q13309
UPID:
SKP2_HUMAN
Alternative names:
Cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2
Alternative UPACC:
Q13309; A8K5E0; B4DJT4; Q8TDZ0; Q8TDZ1; Q9BV69
Background:
S-phase kinase-associated protein 2 (Skp2), also known as F-box protein Skp2 or p45skp2, plays a pivotal role in cell cycle progression, signal transduction, and transcription. It functions as a substrate recognition component of the SCF E3 ubiquitin-protein ligase complex, targeting proteins for ubiquitination and proteasomal degradation. Skp2 specifically recognizes and mediates the degradation of several key regulatory proteins, including phosphorylated CDKN1B/p27kip, crucial for G1/S transition, and has roles in the degradation of ORC1, CDT1, RBL2, and others.
Therapeutic significance:
Understanding the role of S-phase kinase-associated protein 2 could open doors to potential therapeutic strategies.